Cancer Discovery

Eureka Therapeutics Achieves Regression of Metastatic Liver Cancer Using T-Cell Therapy

Eureka Therapeutics, a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system, announced preliminary safety and clinical results from its ongoing proof-of-concept study of ET140202 T-cell therapy in AFP-positive patients with hepatocellular carcinoma (HCC), the most prevalent form of liver cancer. The data was presented on September 5th in the late-breaking abstracts session of the
Biotechnology

NUS and Harvard scientists develop novel drug that could potentially treat liver cancer more effectively

 A research team led by scientists from the Cancer Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma (HCC) or primary liver cancer. This landmark discovery opens door for more effective treatment of liver cancer with less side effects. The international team comprises researchers from Brigham and Women’s Hospital at
cancer Cancer Discovery

Mayo Clinic Researchers Take a Step Closer to Developing a DNA Test for Liver Cancer

A group of researchers from Mayo Clinic and Exact Sciences Corporation have completed a phase II study comparing a set of DNA markers to alpha fetoprotein as a method to test for liver cancer. The researchers presented their findings today at the 2018 Digestive Disease Week conference in Washington, D.C. “We currently test for liver cancer using ultrasound and a blood protein marker called alpha fetoprotein,” says John Kisiel, M.D., a gastroenterologist at Mayo Clinic. “Unfortunately, these tests
Biotechnology cancer Gene Therapy rare diseases

IU Advances Fight Against Hepatitis B with ‘Virus-Cracking’ Molecules

Indiana University researchers have made an important step forward in the design of drugs that fight the hepatitis B virus, which can cause liver failure and liver cancer. It's estimated that 2 billion people worldwide have had a hepatitis B virus infection in their lifetime, with about 250 million -- including 2 million Americans -- living with chronic infection. Although a vaccine exists, there is no cure. The study, published Jan.
cancer

Placental Cells Significantly Inhibit Cancer Cell Growth in Newly Published Study

According to the peer-reviewed article in the journal Scientific Reports, placenta-derived cells called PLX cells, exhibit a strong inhibitory effect on various lines of breast, colorectal, kidney, liver, lung, muscle and skin cancers. The research was conducted over more than two years by Pluristem Therapeutics, Inc., a Haifa-based biotechnology company. The article titled “Human Placental-Derived Adherent Stromal Cells Co-Induced with TNF‑a and IFN‑g Inhibit Triple-Negative Breast Cancer in Nude Mouse Xenograft
Biotechnology cancer Gene Therapy Immunotherapies

Liver Cancer Patients Can Start with Lower Dose of Chemotherapy and Live Just as Long

Penn study shows patients can benefit from fewer side effects and lower treatment costs Patients with the most common type of liver cancer who are taking the chemotherapy drug sorafenib can begin their treatment with a lower dose than is currently considered standard, and it will not affect how long they live when compared to patients who start on the full dose. That finding comes from a new study from
cancer Diabetes

Liver Cancer Drug Shows Promise in Preventing Liver Fibrosis and Treating NASH

Namodenoson, a Phase II drug developed by Can-Fite BioPharma Ltd. (NYSE MKT: CANF), has shown in newly published data that it prevents liver (hepatic) fibrosis progression in preclinical studies. "These latest study results add to the growing body of data that demonstrate Namodenoson's potential efficacy in combating non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH), indications for which there is currently no FDA approved drug. We are
cancer

New Biotechnology Partnership Formed to Develop Liver Cancer Chemotherapeutic

Q BioMed, Inc., a New York City-based biomedical acceleration and development company has entered into an agreement with the Oklahoma Medical Research Foundation (OMRF) and the Rajiv Gandhi Centre for Biotechnology (RGCB) to develop a chemotherapeutic technology to treat liver cancer. The technology will utilize “uttroside B” and the compound’s derivatives as a chemotherapeutic agent against hepatocellular carcinoma. The preclinical efficacy of uttroside B, a potent saponin, against liver cancer
cancer Cancer Discovery

Researchers inhibit tumor growth in new subtype of lung cancer

Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease. A team of investigators led by Elena Levantini, PhD, a research associate in Hematology-Oncology at Beth Israel Deaconess Medical Center (BIDMC), instructor of medicine at Harvard Medical School